Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ESPL1 | Q14674 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP4 | P49662 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14609178 | 0.87 | CDYL (0.33) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16350331 | 0.84 | MAPT (0.42) | MAPTLMNASMN1; SMN2HTTNPSR1 | |
| SCHEMBL12659870 | 0.83 | MAPT (0.46) | MAPTESPL1CASP1CASP3CASP4 | |
| SCHEMBL2492899 | 0.82 | CASP1 (0.48) | ESPL1CYP1A2CASP1CASP3CASP4 | |
| SCHEMBL13234126 | 0.82 | ESPL1 (0.39) | MAPTESPL1CYP1A2CASP1CASP3 | |
| SCHEMBL13234018 | 0.81 | MAPT (0.42) | MAPTESPL1CASP1CASP3CASP4 | |
| SCHEMBL12659865 | 0.81 | CYP1A2 (0.43) | MAPTESPL1CYP1A2CASP1CASP3 | |
| SCHEMBL4494149 | 0.78 | ALDH1A1 (0.37) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4506226 | 0.77 | TDP1 (0.44) | MAPTCYP1A2L3MBTL1LMNAMEN1 | |
| SCHEMBL9092549 | 0.76 | RARA (0.54) | MAPTCASP1CASP3CASP4CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
| CN-101400681-A | Substituted indazole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2009-04-01 | — | — | CN | disclosed |
| US-7462639-B2 | e.g 3-(7,7-Dimethyl-6-oxo-1,5,6,7-tetrahydro-imidazo[4,5-f]indol-2-yl)-1H-pyrazol-4-yl]-carbamic acid benzyl ester; Aurora A (serotonin/threonine) kinase inhibitors; anticarcinogenic agent; colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian cancer, melanoma, neuroblastoma | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| CN-101160312-A | Tricyclic azole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | disclosed |
| CN-101160313-A | Aminopyrazole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879894-A1 | AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060235065-A1 | Aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108489-A1 | AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | MAPT 2890/4885ESPL1 4361/4885CYP1A2 8/4885 |
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | MAPT 2894/4885ESPL1 2128/4885CYP1A2 11/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | MAPT 3710/4885ESPL1 494/4885CYP1A2 4657/4885 |
| US-20060235065-A1 | Aminopyrazole derivatives | CYP3A43, CYP3A5, CYP3A4 | MAPT 3127/4885ESPL1 4295/4885CYP1A2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.